{
    "info": {
        "nct_id": "NCT05593328",
        "official_title": "A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation",
        "inclusion_criteria": "1. Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC).\n2. Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4 in primary tumor or metastasis, assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.\n3. Age ≥ 18 years.\n4. Participants with tumors that have progressed on an oxaliplatin/fluoropyrimidine--based regimen with or without bevacizumab.\n\n   1. Participants must have had systemic therapy within 180 days of the screening visit.\n   2. Participants must have, at any time previously, received oxaliplatin-based chemotherapy with or without bevacizumab (≥ 6 weeks in duration).\n   3. Participants who received oxaliplatin/fluoropyrimidine-based neoadjuvant, adjuvant, and/or fluoropyrimidine maintenance or adjuvant therapy and have disease recurrence or progression > 6 months from their last dose of oxaliplatin will be required to have received oxaliplatin/fluoropyrimidine-based therapy with or without bevacizumab as first-line treatment for metastatic disease.\n   4. Participants who received an oxaliplatin-based regimen in the first-line setting and discontinued oxaliplatin because of toxicity or who received oxaliplatin for maintenance therapy are eligible as long as progression occurred < 6 months after the last dose of oxaliplatin therapy for advanced metastatic disease. It is recommended that these participants be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility. Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible.\n5. Participants must not have received prior treatment with irinotecan.\n6. FOLFIRI therapy is appropriate for the participant as determined by the Investigator.\n7. Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib. Only participants with measurable disease as defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) are eligible for enrollment. CT is the preferred imaging modality, but MRI is also accepted. All subsequent scans must consistently use the same imaging modality for comparison with the Screening scan throughout the study.\n8. Must have acceptable organ function\n9. Signed informed consent to provide blood sample(s) for specific correlative assays\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Concomitant KRAS or NRAS and BRAF-V600 mutation or Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR).\n2. Anti-cancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug. The exception is a single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.\n3. More than 1 prior chemotherapy regimen administered in the metastatic setting.\n4. Major surgery within 6 weeks prior to enrollment.\n5. Untreated or symptomatic brain metastasis.\n6. Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).\n7. Unable or unwilling to swallow study drug.\n8. Known hypersensitivity to fluoropyrimidine or leucovorin.\n9. Known hypersensitivity to irinotecan.\n10. Abnormal glucuronidation of bilirubin; known Gilbert's syndrome.\n11. QT interval:\n\n    1. Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation that are readily corrected (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility.\n    2. Planned concomitant use of medications known to prolong the QT/QTc interval according to institutional guidelines.\n    3. Presence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.\n12. Use of strong cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C19 (CYP2C19) inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who can be switched to alternate therapy are not excluded. Inhibitors should be stopped at least 1 week prior to the first dose of protocol therapy and inducers should be stopped at least 2 weeks prior to initiation of protocol therapy.\n13. The following are exclusion criteria for bevacizumab:\n\n    1. History of cardiac disease: Congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA); active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease.\n    2. Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management) and prior history of hypertensive crisis or hypertensive encephalopathy.\n    3. History of arterial thrombotic or embolic events (within 6 months prior to study entry).\n    4. Significant vascular disease (eg, aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease).\n    5. Evidence of bleeding diathesis or clinically significant coagulopathy.\n    6. Major surgical procedure (including open biopsy, significant traumatic injury, etc) within 28 days, or anticipation of the need for major surgical procedure during the study, and minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment.\n    7. Proteinuria at Screening as demonstrated by urinalysis with proteinuria ≥2+ (participants discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤1 g of protein in 24 hours to be eligible).\n    8. Abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within the past 6 months.\n    9. Ongoing serious, non-healing wound, ulcer, or bone fracture\n    10. Known hypersensitivity to any component of bevacizumab\n    11. History of reversible posterior leukoencephalopathy syndrome",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "9. Signed informed consent to provide blood sample(s) for specific correlative assays",
                "criterions": [
                    {
                        "exact_snippets": "Signed informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide blood sample(s)",
                        "criterion": "blood sample provision",
                        "requirement": {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for specific correlative assays",
                        "criterion": "correlative assay participation",
                        "requirement": {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Signed informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "provide blood sample(s)",
                        "criterion": "blood sample provision",
                        "requirement": {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for specific correlative assays",
                        "criterion": "correlative assay participation",
                        "requirement": {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. FOLFIRI therapy is appropriate for the participant as determined by the Investigator.",
                "criterions": [
                    {
                        "exact_snippets": "FOLFIRI therapy is appropriate for the participant as determined by the Investigator",
                        "criterion": "appropriateness of FOLFIRI therapy",
                        "requirement": {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "FOLFIRI therapy is appropriate for the participant as determined by the Investigator",
                        "criterion": "appropriateness of FOLFIRI therapy",
                        "requirement": {
                            "requirement_type": "determined by",
                            "expected_value": "Investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "FOLFIRI therapy is appropriate for the participant as determined by the Investigator",
                        "criterion": "appropriateness of FOLFIRI therapy",
                        "requirement": {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "FOLFIRI therapy is appropriate for the participant as determined by the Investigator",
                        "criterion": "appropriateness of FOLFIRI therapy",
                        "requirement": {
                            "requirement_type": "determined by",
                            "expected_value": "Investigator"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Age ≥ 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Participants must not have received prior treatment with irinotecan.",
                "criterions": [
                    {
                        "exact_snippets": "must not have received prior treatment with irinotecan",
                        "criterion": "prior treatment with irinotecan",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "must not have received prior treatment with irinotecan",
                        "criterion": "prior treatment with irinotecan",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Participants must have had systemic therapy within 180 days of the screening visit.",
                "criterions": [
                    {
                        "exact_snippets": "Participants must have had systemic therapy within 180 days of the screening visit.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days since screening visit"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants must have had systemic therapy within 180 days of the screening visit.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days since screening visit"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Participants who received an oxaliplatin-based regimen in the first-line setting and discontinued oxaliplatin because of toxicity or who received oxaliplatin for maintenance therapy are eligible as long as progression occurred < 6 months after the last dose of oxaliplatin therapy for advanced metastatic disease. It is recommended that these participants be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility. Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Participants who received an oxaliplatin-based regimen in the first-line setting",
                        "criterion": "oxaliplatin-based regimen in first-line setting",
                        "requirement": {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "discontinued oxaliplatin because of toxicity",
                        "criterion": "discontinuation of oxaliplatin due to toxicity",
                        "requirement": {
                            "requirement_type": "reason for discontinuation",
                            "expected_value": "toxicity"
                        }
                    },
                    {
                        "exact_snippets": "received oxaliplatin for maintenance therapy",
                        "criterion": "oxaliplatin for maintenance therapy",
                        "requirement": {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "progression occurred < 6 months after the last dose of oxaliplatin therapy for advanced metastatic disease",
                        "criterion": "progression after oxaliplatin therapy",
                        "requirement": {
                            "requirement_type": "time to progression after last oxaliplatin dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility",
                        "criterion": "re-challenge with oxaliplatin/fluoropyrimidine therapy and subsequent progression",
                        "requirement": {
                            "requirement_type": "re-challenge with oxaliplatin/fluoropyrimidine",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility",
                        "criterion": "re-challenge with oxaliplatin/fluoropyrimidine therapy and subsequent progression",
                        "requirement": {
                            "requirement_type": "progression after re-challenge",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible",
                        "criterion": "oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity precluding re-challenge",
                        "requirement": {
                            "requirement_type": "presence of neuropathy or hypersensitivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible",
                        "criterion": "oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity precluding re-challenge",
                        "requirement": {
                            "requirement_type": "ability to be rechallenged with oxaliplatin",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "Participants who received an oxaliplatin-based regimen in the first-line setting",
                                                "criterion": "oxaliplatin-based regimen in first-line setting",
                                                "requirement": {
                                                    "requirement_type": "treatment history",
                                                    "expected_value": true
                                                }
                                            },
                                            {
                                                "exact_snippets": "discontinued oxaliplatin because of toxicity",
                                                "criterion": "discontinuation of oxaliplatin due to toxicity",
                                                "requirement": {
                                                    "requirement_type": "reason for discontinuation",
                                                    "expected_value": "toxicity"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "received oxaliplatin for maintenance therapy",
                                        "criterion": "oxaliplatin for maintenance therapy",
                                        "requirement": {
                                            "requirement_type": "treatment history",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "progression occurred < 6 months after the last dose of oxaliplatin therapy for advanced metastatic disease",
                                "criterion": "progression after oxaliplatin therapy",
                                "requirement": {
                                    "requirement_type": "time to progression after last oxaliplatin dose",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility",
                                "criterion": "re-challenge with oxaliplatin/fluoropyrimidine therapy and subsequent progression",
                                "requirement": {
                                    "requirement_type": "re-challenge with oxaliplatin/fluoropyrimidine",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility",
                                "criterion": "re-challenge with oxaliplatin/fluoropyrimidine therapy and subsequent progression",
                                "requirement": {
                                    "requirement_type": "progression after re-challenge",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible",
                                "criterion": "oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity precluding re-challenge",
                                "requirement": {
                                    "requirement_type": "presence of neuropathy or hypersensitivity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible",
                                "criterion": "oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity precluding re-challenge",
                                "requirement": {
                                    "requirement_type": "ability to be rechallenged with oxaliplatin",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Must have acceptable organ function",
                "criterions": [
                    {
                        "exact_snippets": "Must have acceptable organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have acceptable organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "8. Abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within the past 6 months.",
                "criterions": [
                    {
                        "exact_snippets": "Abdominal fistula ... within the past 6 months.",
                        "criterion": "abdominal fistula",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "gastrointestinal perforation ... within the past 6 months.",
                        "criterion": "gastrointestinal perforation",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "peptic ulcer ... within the past 6 months.",
                        "criterion": "peptic ulcer",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intra-abdominal abscess within the past 6 months.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Abdominal fistula ... within the past 6 months.",
                        "criterion": "abdominal fistula",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "gastrointestinal perforation ... within the past 6 months.",
                        "criterion": "gastrointestinal perforation",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "peptic ulcer ... within the past 6 months.",
                        "criterion": "peptic ulcer",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intra-abdominal abscess within the past 6 months.",
                        "criterion": "intra-abdominal abscess",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. QT interval:",
                "criterions": [
                    {
                        "exact_snippets": "QT interval:",
                        "criterion": "QT interval",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "QT interval:",
                        "criterion": "QT interval",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Planned concomitant use of medications known to prolong the QT/QTc interval according to institutional guidelines.",
                "criterions": [
                    {
                        "exact_snippets": "Planned concomitant use of medications known to prolong the QT/QTc interval",
                        "criterion": "concomitant use of medications known to prolong the QT/QTc interval",
                        "requirement": {
                            "requirement_type": "planned use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Planned concomitant use of medications known to prolong the QT/QTc interval",
                        "criterion": "concomitant use of medications known to prolong the QT/QTc interval",
                        "requirement": {
                            "requirement_type": "planned use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Evidence of bleeding diathesis or clinically significant coagulopathy.",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant coagulopathy",
                        "criterion": "coagulopathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Evidence of bleeding diathesis",
                        "criterion": "bleeding diathesis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant coagulopathy",
                        "criterion": "coagulopathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Unable or unwilling to swallow study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Unable ... to swallow study drug",
                        "criterion": "ability to swallow study drug",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to swallow study drug",
                        "criterion": "willingness to swallow study drug",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Unable ... to swallow study drug",
                            "criterion": "ability to swallow study drug",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "unwilling to swallow study drug",
                            "criterion": "willingness to swallow study drug",
                            "requirement": {
                                "requirement_type": "willingness",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Concomitant KRAS or NRAS and BRAF-V600 mutation or Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR).",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                        "criterion": "KRAS mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                        "criterion": "NRAS mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                        "criterion": "BRAF-V600 mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR)",
                        "criterion": "Microsatellite Instability High (MSI-H)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR)",
                        "criterion": "Deficient Mismatch Repair (dMMR)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                                        "criterion": "KRAS mutation",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                                        "criterion": "NRAS mutation",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Concomitant KRAS or NRAS and BRAF-V600 mutation",
                                "criterion": "BRAF-V600 mutation",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR)",
                        "criterion": "Microsatellite Instability High (MSI-H)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR)",
                        "criterion": "Deficient Mismatch Repair (dMMR)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Anti-cancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug. The exception is a single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                "criterions": [
                    {
                        "exact_snippets": "Anti-cancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug.",
                        "criterion": "anti-cancer chemotherapy or biologic therapy administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    },
                    {
                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                        "criterion": "single dose of radiation for pain control",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "Gray"
                            }
                        }
                    },
                    {
                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                        "criterion": "single dose of radiation for pain control",
                        "requirement": {
                            "requirement_type": "intent",
                            "expected_value": "palliative for pain control"
                        }
                    },
                    {
                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                        "criterion": "single dose of radiation for pain control",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                        "criterion": "single dose of radiation for pain control",
                        "requirement": {
                            "requirement_type": "target lesion involvement",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Anti-cancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug.",
                        "criterion": "anti-cancer chemotherapy or biologic therapy administration",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                                        "criterion": "single dose of radiation for pain control",
                                        "requirement": {
                                            "requirement_type": "dose",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 8,
                                                "unit": "Gray"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                                        "criterion": "single dose of radiation for pain control",
                                        "requirement": {
                                            "requirement_type": "intent",
                                            "expected_value": "palliative for pain control"
                                        }
                                    },
                                    {
                                        "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                                        "criterion": "single dose of radiation for pain control",
                                        "requirement": {
                                            "requirement_type": "recency",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 14,
                                                "unit": "days before enrollment"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.",
                                "criterion": "single dose of radiation for pain control",
                                "requirement": {
                                    "requirement_type": "target lesion involvement",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Known hypersensitivity to irinotecan.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to irinotecan",
                        "criterion": "hypersensitivity to irinotecan",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Known hypersensitivity to irinotecan",
                    "criterion": "hypersensitivity to irinotecan",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Presence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of risk factors for torsade de pointes",
                        "criterion": "risk factors for torsade de pointes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of Long QT Syndrome",
                        "criterion": "family history of Long QT Syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncorrected hypokalemia",
                        "criterion": "uncorrected hypokalemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Presence of risk factors for torsade de pointes",
                        "criterion": "risk factors for torsade de pointes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "family history of Long QT Syndrome",
                                "criterion": "family history of Long QT Syndrome",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "uncorrected hypokalemia",
                                "criterion": "uncorrected hypokalemia",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Major surgery within 6 weeks prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 6 weeks prior to enrollment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Major surgery within 6 weeks prior to enrollment.",
                    "criterion": "major surgery",
                    "requirement": {
                        "requirement_type": "time since surgery",
                        "expected_value": {
                            "operator": ">=",
                            "value": 6,
                            "unit": "weeks"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Known hypersensitivity to any component of bevacizumab",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to any component of bevacizumab",
                        "criterion": "hypersensitivity to bevacizumab components",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to any component of bevacizumab",
                        "criterion": "hypersensitivity to bevacizumab components",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation that are readily corrected (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility.",
                "criterions": [
                    {
                        "exact_snippets": "Fridericia's correction (QTcF) > 470 milliseconds",
                        "criterion": "QTcF (Fridericia's corrected QT interval)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "milliseconds"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Fridericia's correction (QTcF) > 470 milliseconds",
                        "criterion": "QTcF (Fridericia's corrected QT interval)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "milliseconds"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Ongoing serious, non-healing wound, ulcer, or bone fracture",
                "criterions": [
                    {
                        "exact_snippets": "Ongoing serious, non-healing wound",
                        "criterion": "wound",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing wound",
                        "criterion": "wound",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": "serious"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing wound",
                        "criterion": "wound",
                        "requirement": {
                            "requirement_type": "ongoing",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                        "criterion": "ulcer",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                        "criterion": "ulcer",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": "serious"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                        "criterion": "ulcer",
                        "requirement": {
                            "requirement_type": "ongoing",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                        "criterion": "bone fracture",
                        "requirement": {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                        "criterion": "bone fracture",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": "serious"
                        }
                    },
                    {
                        "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                        "criterion": "bone fracture",
                        "requirement": {
                            "requirement_type": "ongoing",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Ongoing serious, non-healing wound",
                                "criterion": "wound",
                                "requirement": {
                                    "requirement_type": "healing status",
                                    "expected_value": "non-healing"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing wound",
                                "criterion": "wound",
                                "requirement": {
                                    "requirement_type": "seriousness",
                                    "expected_value": "serious"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing wound",
                                "criterion": "wound",
                                "requirement": {
                                    "requirement_type": "ongoing",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                                "criterion": "ulcer",
                                "requirement": {
                                    "requirement_type": "healing status",
                                    "expected_value": "non-healing"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                                "criterion": "ulcer",
                                "requirement": {
                                    "requirement_type": "seriousness",
                                    "expected_value": "serious"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... ulcer",
                                "criterion": "ulcer",
                                "requirement": {
                                    "requirement_type": "ongoing",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                                "criterion": "bone fracture",
                                "requirement": {
                                    "requirement_type": "healing status",
                                    "expected_value": "non-healing"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                                "criterion": "bone fracture",
                                "requirement": {
                                    "requirement_type": "seriousness",
                                    "expected_value": "serious"
                                }
                            },
                            {
                                "exact_snippets": "Ongoing serious, non-healing ... bone fracture",
                                "criterion": "bone fracture",
                                "requirement": {
                                    "requirement_type": "ongoing",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Abnormal glucuronidation of bilirubin; known Gilbert's syndrome.",
                "criterions": [
                    {
                        "exact_snippets": "Abnormal glucuronidation of bilirubin",
                        "criterion": "glucuronidation of bilirubin",
                        "requirement": {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known Gilbert's syndrome",
                        "criterion": "Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Abnormal glucuronidation of bilirubin",
                        "criterion": "glucuronidation of bilirubin",
                        "requirement": {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known Gilbert's syndrome",
                        "criterion": "Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Untreated or symptomatic brain metastasis.",
                "criterions": [
                    {
                        "exact_snippets": "Untreated ... brain metastasis",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "symptomatic brain metastasis",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Untreated ... brain metastasis",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "symptomatic brain metastasis",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. More than 1 prior chemotherapy regimen administered in the metastatic setting.",
                "criterions": [
                    {
                        "exact_snippets": "More than 1 prior chemotherapy regimen administered in the metastatic setting.",
                        "criterion": "prior chemotherapy regimens in the metastatic setting",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "More than 1 prior chemotherapy regimen administered in the metastatic setting.",
                        "criterion": "prior chemotherapy regimens in the metastatic setting",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management) and prior history of hypertensive crisis or hypertensive encephalopathy.",
                "criterions": [
                    {
                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "medical management",
                            "expected_value": "despite optimal medical management"
                        }
                    },
                    {
                        "exact_snippets": "prior history of hypertensive crisis or hypertensive encephalopathy",
                        "criterion": "hypertensive crisis or hypertensive encephalopathy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                                                "criterion": "hypertension",
                                                "requirement": {
                                                    "requirement_type": "control status",
                                                    "expected_value": "uncontrolled"
                                                }
                                            },
                                            {
                                                "or_criteria": [
                                                    {
                                                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                                                        "criterion": "hypertension",
                                                        "requirement": {
                                                            "requirement_type": "systolic blood pressure",
                                                            "expected_value": {
                                                                "operator": ">",
                                                                "value": 150,
                                                                "unit": "mmHg"
                                                            }
                                                        }
                                                    },
                                                    {
                                                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                                                        "criterion": "hypertension",
                                                        "requirement": {
                                                            "requirement_type": "diastolic blood pressure",
                                                            "expected_value": {
                                                                "operator": ">",
                                                                "value": 90,
                                                                "unit": "mmHg"
                                                            }
                                                        }
                                                    }
                                                ]
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management)",
                                        "criterion": "hypertension",
                                        "requirement": {
                                            "requirement_type": "medical management",
                                            "expected_value": "despite optimal medical management"
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "prior history of hypertensive crisis or hypertensive encephalopathy",
                                "criterion": "hypertensive crisis or hypertensive encephalopathy",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. The following are exclusion criteria for bevacizumab:",
                "criterions": [
                    {
                        "exact_snippets": "exclusion criteria for bevacizumab",
                        "criterion": "bevacizumab exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "exclusion criteria for bevacizumab",
                        "criterion": "bevacizumab exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. History of arterial thrombotic or embolic events (within 6 months prior to study entry).",
                "criterions": [
                    {
                        "exact_snippets": "History of arterial thrombotic or embolic events (within 6 months prior to study entry)",
                        "criterion": "arterial thrombotic events",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of arterial thrombotic or embolic events (within 6 months prior to study entry)",
                        "criterion": "arterial embolic events",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of arterial thrombotic or embolic events (within 6 months prior to study entry)",
                        "criterion": "arterial thrombotic events",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of arterial thrombotic or embolic events (within 6 months prior to study entry)",
                        "criterion": "arterial embolic events",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).",
                "criterions": [
                    {
                        "exact_snippets": "Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)",
                        "criterion": "gastrointestinal (GI) disorder(s)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)",
                        "criterion": "gastrointestinal (GI) disorder(s)",
                        "requirement": {
                            "requirement_type": "impact on absorption of oral agent",
                            "expected_value": "would significantly impede"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)",
                        "criterion": "gastrointestinal (GI) disorder(s)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)",
                        "criterion": "gastrointestinal (GI) disorder(s)",
                        "requirement": {
                            "requirement_type": "impact on absorption of oral agent",
                            "expected_value": "would significantly impede"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. History of cardiac disease: Congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA); active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease.",
                "criterions": [
                    {
                        "exact_snippets": "Congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA)",
                        "criterion": "congestive heart failure (CHF)",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "active coronary artery disease",
                        "criterion": "coronary artery disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction within 6 months prior to study entry",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unevaluated new onset angina within 3 months",
                        "criterion": "new onset angina",
                        "requirement": {
                            "requirement_type": "evaluation status",
                            "expected_value": "unevaluated"
                        }
                    },
                    {
                        "exact_snippets": "unevaluated new onset angina within 3 months",
                        "criterion": "new onset angina",
                        "requirement": {
                            "requirement_type": "time since onset",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina (angina symptoms at rest)",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "requirement for anti-arrhythmic therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease",
                        "criterion": "cardiac arrhythmias",
                        "requirement": {
                            "requirement_type": "disease stability",
                            "expected_value": "not stable/controlled unless deemed stable/controlled by Investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA)",
                                "criterion": "congestive heart failure (CHF)",
                                "requirement": {
                                    "requirement_type": "NYHA class",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "active coronary artery disease",
                                "criterion": "coronary artery disease",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "myocardial infarction within 6 months prior to study entry",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "time since event",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "unevaluated new onset angina within 3 months",
                                        "criterion": "new onset angina",
                                        "requirement": {
                                            "requirement_type": "evaluation status",
                                            "expected_value": "unevaluated"
                                        }
                                    },
                                    {
                                        "exact_snippets": "unevaluated new onset angina within 3 months",
                                        "criterion": "new onset angina",
                                        "requirement": {
                                            "requirement_type": "time since onset",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "months"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "unstable angina (angina symptoms at rest)",
                                "criterion": "unstable angina",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": "unstable"
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease",
                                        "criterion": "cardiac arrhythmias",
                                        "requirement": {
                                            "requirement_type": "requirement for anti-arrhythmic therapy",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease",
                                        "criterion": "cardiac arrhythmias",
                                        "requirement": {
                                            "requirement_type": "disease stability",
                                            "expected_value": "not stable/controlled unless deemed stable/controlled by Investigator"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Significant vascular disease (eg, aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease).",
                "criterions": [
                    {
                        "exact_snippets": "Significant vascular disease (eg, aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease)",
                        "criterion": "vascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "aortic aneurysm",
                        "criterion": "aortic aneurysm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "aortic dissection",
                        "criterion": "aortic dissection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic peripheral vascular disease",
                        "criterion": "peripheral vascular disease",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Significant vascular disease (eg, aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease)",
                        "criterion": "vascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "aortic aneurysm",
                        "criterion": "aortic aneurysm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "aortic dissection",
                        "criterion": "aortic dissection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic peripheral vascular disease",
                        "criterion": "peripheral vascular disease",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Known hypersensitivity to fluoropyrimidine or leucovorin.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to fluoropyrimidine",
                        "criterion": "hypersensitivity to fluoropyrimidine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... leucovorin",
                        "criterion": "hypersensitivity to leucovorin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to fluoropyrimidine",
                        "criterion": "hypersensitivity to fluoropyrimidine",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... leucovorin",
                        "criterion": "hypersensitivity to leucovorin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. History of reversible posterior leukoencephalopathy syndrome",
                "criterions": [
                    {
                        "exact_snippets": "History of reversible posterior leukoencephalopathy syndrome",
                        "criterion": "reversible posterior leukoencephalopathy syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of reversible posterior leukoencephalopathy syndrome",
                    "criterion": "reversible posterior leukoencephalopathy syndrome",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "1. Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC).",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC)",
                        "criterion": "colorectal cancer (CRC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC)",
                        "criterion": "colorectal cancer (CRC)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC)",
                        "criterion": "colorectal cancer (CRC)",
                        "requirement": {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "metastatic",
                                "unresectable"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Participants who received oxaliplatin/fluoropyrimidine-based neoadjuvant, adjuvant, and/or fluoropyrimidine maintenance or adjuvant therapy and have disease recurrence or progression > 6 months from their last dose of oxaliplatin will be required to have received oxaliplatin/fluoropyrimidine-based therapy with or without bevacizumab as first-line treatment for metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "Participants who received oxaliplatin/fluoropyrimidine-based neoadjuvant, adjuvant, and/or fluoropyrimidine maintenance or adjuvant therapy",
                        "criterion": "prior therapy with oxaliplatin/fluoropyrimidine-based regimens",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "disease recurrence or progression > 6 months from their last dose of oxaliplatin",
                        "criterion": "time to disease recurrence or progression after last oxaliplatin dose",
                        "requirement": {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "will be required to have received oxaliplatin/fluoropyrimidine-based therapy with or without bevacizumab as first-line treatment for metastatic disease",
                        "criterion": "first-line treatment for metastatic disease",
                        "requirement": {
                            "requirement_type": "regimen",
                            "expected_value": [
                                "oxaliplatin/fluoropyrimidine-based therapy",
                                "oxaliplatin/fluoropyrimidine-based therapy with bevacizumab"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib. Only participants with measurable disease as defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) are eligible for enrollment. CT is the preferred imaging modality, but MRI is also accepted. All subsequent scans must consistently use the same imaging modality for comparison with the Screening scan throughout the study.",
                "criterions": [
                    {
                        "exact_snippets": "Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib.",
                        "criterion": "imaging of disease sites",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": [
                                "CT",
                                "MRI",
                                "other scans"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib.",
                        "criterion": "imaging of disease sites",
                        "requirement": {
                            "requirement_type": "anatomical regions",
                            "expected_value": [
                                "chest",
                                "abdomen",
                                "pelvis"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib.",
                        "criterion": "imaging of disease sites",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to first dose"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Only participants with measurable disease as defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) are eligible for enrollment.",
                        "criterion": "measurable disease per RECIST v1.1",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All subsequent scans must consistently use the same imaging modality for comparison with the Screening scan throughout the study.",
                        "criterion": "imaging modality consistency",
                        "requirement": {
                            "requirement_type": "consistency",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Participants must have, at any time previously, received oxaliplatin-based chemotherapy with or without bevacizumab (≥ 6 weeks in duration).",
                "criterions": [
                    {
                        "exact_snippets": "received oxaliplatin-based chemotherapy ... (≥ 6 weeks in duration)",
                        "criterion": "oxaliplatin-based chemotherapy",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "received oxaliplatin-based chemotherapy ... (≥ 6 weeks in duration)",
                        "criterion": "oxaliplatin-based chemotherapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with or without bevacizumab",
                        "criterion": "bevacizumab",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": "optional"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "received oxaliplatin-based chemotherapy ... (≥ 6 weeks in duration)",
                        "criterion": "oxaliplatin-based chemotherapy",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "received oxaliplatin-based chemotherapy ... (≥ 6 weeks in duration)",
                        "criterion": "oxaliplatin-based chemotherapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Participants with tumors that have progressed on an oxaliplatin/fluoropyrimidine--based regimen with or without bevacizumab.",
                "criterions": [
                    {
                        "exact_snippets": "tumors that have progressed on an oxaliplatin/fluoropyrimidine--based regimen",
                        "criterion": "tumor progression on oxaliplatin/fluoropyrimidine-based regimen",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "tumors that have progressed on an oxaliplatin/fluoropyrimidine--based regimen",
                        "criterion": "tumor progression on oxaliplatin/fluoropyrimidine-based regimen",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": "oxaliplatin/fluoropyrimidine-based regimen"
                        }
                    },
                    {
                        "exact_snippets": "with or without bevacizumab",
                        "criterion": "prior treatment with bevacizumab",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "with bevacizumab",
                                "without bevacizumab"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4 in primary tumor or metastasis, assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.",
                "criterions": [
                    {
                        "exact_snippets": "Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4",
                        "criterion": "KRAS or NRAS mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4",
                        "criterion": "KRAS or NRAS mutation",
                        "requirement": {
                            "requirement_type": "gene",
                            "expected_value": [
                                "KRAS",
                                "NRAS"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4",
                        "criterion": "KRAS or NRAS mutation",
                        "requirement": {
                            "requirement_type": "exon",
                            "expected_value": [
                                "2",
                                "3",
                                "4"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "in primary tumor or metastasis",
                        "criterion": "tumor location for mutation testing",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "primary tumor",
                                "metastasis"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory",
                        "criterion": "laboratory certification for mutation assessment",
                        "requirement": {
                            "requirement_type": "certification",
                            "expected_value": "CLIA-certified"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "12. Use of strong cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C19 (CYP2C19) inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who can be switched to alternate therapy are not excluded. Inhibitors should be stopped at least 1 week prior to the first dose of protocol therapy and inducers should be stopped at least 2 weeks prior to initiation of protocol therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Use of strong cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C19 (CYP2C19) inhibitors or strong CYP3A4 inducers.",
                        "criterion": "use of strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Participants currently receiving these agents who can be switched to alternate therapy are not excluded.",
                        "criterion": "ability to switch from strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers to alternate therapy",
                        "requirement": {
                            "requirement_type": "ability to switch to alternate therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Inhibitors should be stopped at least 1 week prior to the first dose of protocol therapy",
                        "criterion": "discontinuation of strong CYP3A4 or CYP2C19 inhibitors prior to protocol therapy",
                        "requirement": {
                            "requirement_type": "discontinuation time before protocol therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "inducers should be stopped at least 2 weeks prior to initiation of protocol therapy.",
                        "criterion": "discontinuation of strong CYP3A4 inducers prior to protocol therapy",
                        "requirement": {
                            "requirement_type": "discontinuation time before protocol therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "use of strong cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C19 (CYP2C19) inhibitors or strong CYP3A4 inducers.",
                                "criterion": "use of strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "not_criteria": {
                                        "exact_snippets": "Participants currently receiving these agents who can be switched to alternate therapy are not excluded.",
                                        "criterion": "ability to switch from strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers to alternate therapy",
                                        "requirement": {
                                            "requirement_type": "ability to switch to alternate therapy",
                                            "expected_value": true
                                        }
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "discontinuation of strong CYP3A4 or CYP2C19 inhibitors prior to protocol therapy",
                                "criterion": "discontinuation of strong CYP3A4 or CYP2C19 inhibitors prior to protocol therapy",
                                "requirement": {
                                    "requirement_type": "discontinuation time before protocol therapy",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "discontinuation of strong CYP3A4 inducers prior to protocol therapy",
                                "criterion": "discontinuation of strong CYP3A4 inducers prior to protocol therapy",
                                "requirement": {
                                    "requirement_type": "discontinuation time before protocol therapy",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Major surgical procedure (including open biopsy, significant traumatic injury, etc) within 28 days, or anticipation of the need for major surgical procedure during the study, and minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgical procedure ... within 28 days",
                        "criterion": "major surgical procedure",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "anticipation of the need for major surgical procedure during the study",
                        "criterion": "anticipated need for major surgical procedure",
                        "requirement": {
                            "requirement_type": "anticipated during study",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment",
                        "criterion": "minor surgical procedure (excluding placement of a vascular access device)",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Major surgical procedure ... within 28 days",
                                "criterion": "major surgical procedure",
                                "requirement": {
                                    "requirement_type": "time since procedure",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "anticipation of the need for major surgical procedure during the study",
                                "criterion": "anticipated need for major surgical procedure",
                                "requirement": {
                                    "requirement_type": "anticipated during study",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment",
                        "criterion": "minor surgical procedure (excluding placement of a vascular access device)",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Proteinuria at Screening as demonstrated by urinalysis with proteinuria ≥2+ (participants discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤1 g of protein in 24 hours to be eligible).",
                "criterions": [
                    {
                        "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria ≥2+",
                        "criterion": "proteinuria at screening",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria ≥2+",
                        "criterion": "proteinuria at screening",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤1 g of protein in 24 hours to be eligible",
                        "criterion": "protein excretion in 24-hour urine collection",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g/24h"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria \u001a2+",
                                "criterion": "proteinuria at screening",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria \u001a2+",
                                "criterion": "proteinuria at screening",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "+"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "participants discovered to have \u001a2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \u001a1 g of protein in 24 hours to be eligible",
                                    "criterion": "protein excretion in 24-hour urine collection",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 1,
                                            "unit": "g/24h"
                                        }
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria \u001a2+",
                                "criterion": "proteinuria at screening",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Proteinuria at Screening as demonstrated by urinalysis with proteinuria \u001a2+",
                                "criterion": "proteinuria at screening",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "+"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "participants discovered to have \u001a2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \u001a1 g of protein in 24 hours to be eligible",
                                "criterion": "protein excretion in 24-hour urine collection",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "g/24h"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}